Trials / Unknown
UnknownNCT04525378
MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome
Mesenchymal Stromal Cell-based Therapy for COVID-19-associated Acute Respiratory Distress Syndrome: a Pilot Clinical Study
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- D'Or Institute for Research and Education · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Considering the potential of mesenchymal stromal cells (MSCs) in the treatment of lung injuries by COVID-19, this pilot clinical trial evaluates the safety and potential efficacy of the cell therapy, administered intravenously, in patients with pneumonia associated with COVID-19-associated acute respiratory distress syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Mesenchymal stromal cell-based therapy | Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose) |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2020-09-30
- Completion
- 2020-10-31
- First posted
- 2020-08-25
- Last updated
- 2020-08-26
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT04525378. Inclusion in this directory is not an endorsement.